$SLNO
SOLENO THERAPEUTICS INC

2019 Q2 Form 10-Q Financial Statement

#000156459019018686 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.700M $2.010M $1.870M
YoY Change -3.95% 7.49% 78.78%
% of Gross Profit
Research & Development $3.750M $2.760M $1.180M
YoY Change 118.79% 133.9% 260.86%
% of Gross Profit
Depreciation & Amortization $490.0K $490.0K $490.0K
YoY Change 0.0% 0.0% 226.67%
% of Gross Profit
Operating Expenses $5.623M $4.978M $3.475M
YoY Change 64.75% 43.25% 153.1%
Operating Profit -$5.623M -$4.978M -$3.475M
YoY Change 64.75% 43.25% 153.1%
Interest Expense -$170.0K -$190.0K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$4.385M -$2.052M $185.0K
YoY Change 36.1% -1209.19% -127.53%
Pretax Income -$10.01M -$7.030M -$3.290M
YoY Change 50.75% 113.68% 60.49%
Income Tax
% Of Pretax Income
Net Earnings -$10.01M -$7.030M -$3.804M
YoY Change 41.8% 84.81% 31.76%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$315.0K -$221.3K -$194.6K
COMMON SHARES
Basic Shares Outstanding 31.78M 31.76M 19.49M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.13M $20.19M $14.87M
YoY Change 28.12% 35.78% 41.08%
Cash & Equivalents $15.50M $19.40M $14.87M
Short-Term Investments $620.0K $790.0K
Other Short-Term Assets $470.0K $600.0K $940.0K
YoY Change -34.72% -36.17% 213.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $16.62M $20.87M $15.81M
YoY Change 24.82% 31.99% 33.97%
LONG-TERM ASSETS
Property, Plant & Equipment $22.00K $19.00K $17.00K
YoY Change 69.23% 11.76% -81.72%
Goodwill
YoY Change
Intangibles $17.50M $17.98M $19.93M
YoY Change -10.0% -9.76%
Long-Term Investments
YoY Change
Other Assets $126.0K
YoY Change 0.0%
Total Long-Term Assets $17.52M $18.00M $20.52M
YoY Change -12.55% -12.28% -6.99%
TOTAL ASSETS
Total Short-Term Assets $16.62M $20.87M $15.81M
Total Long-Term Assets $17.52M $18.00M $20.52M
Total Assets $34.13M $38.87M $36.33M
YoY Change 2.37% 6.98% 7.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.740M $1.258M $1.133M
YoY Change 77.37% 11.03% 21.18%
Accrued Expenses $1.120M $990.0K $720.0K
YoY Change 30.23% 37.5% -41.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.855M $2.250M $1.942M
YoY Change 46.79% 15.86% -10.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.44M $12.99M $13.00K
YoY Change 134053.85% 99823.08% -98.92%
Total Long-Term Liabilities $17.44M $12.99M $13.00K
YoY Change 134053.85% 99823.08% -98.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.855M $2.250M $1.942M
Total Long-Term Liabilities $17.44M $12.99M $13.00K
Total Liabilities $20.29M $15.24M $13.08M
YoY Change 21.53% 16.49% 251.49%
SHAREHOLDERS EQUITY
Retained Earnings -$134.1M -$117.5M
YoY Change 14.09% 16.11%
Common Stock $157.7M $140.8M
YoY Change 12.04% 7.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.84M $23.63M $23.25M
YoY Change
Total Liabilities & Shareholders Equity $34.13M $38.87M $36.33M
YoY Change 2.36% 6.98% 7.28%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$10.01M -$7.030M -$3.804M
YoY Change 41.8% 84.81% 31.76%
Depreciation, Depletion And Amortization $490.0K $490.0K $490.0K
YoY Change 0.0% 0.0% 226.67%
Cash From Operating Activities -$3.890M -$3.687M -$2.520M
YoY Change 41.45% 46.31% 15.44%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$10.00K -$10.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 288.0K
YoY Change -100.0% -100.0% -97.12%
NET CHANGE
Cash From Operating Activities -3.890M -3.687M -2.520M
Cash From Investing Activities -10.00K -10.00K 0.000
Cash From Financing Activities 0.000 0.000 288.0K
Net Change In Cash -3.900M -3.697M -2.232M
YoY Change 76.47% 65.64% -128.57%
FREE CASH FLOW
Cash From Operating Activities -$3.890M -$3.687M -$2.520M
Capital Expenditures -$10.00K $10.00K
Free Cash Flow -$3.880M -$3.697M
YoY Change 41.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 slno Minority Interest Investment In Subsidiary
MinorityInterestInvestmentInSubsidiary
788000
CY2018Q4 slno Minority Interest Investment In Subsidiary
MinorityInterestInvestmentInSubsidiary
978000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
20865000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
24670000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12000
CY2019Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17983000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18469000
CY2019Q1 us-gaap Assets
Assets
38867000
CY2018Q4 us-gaap Assets
Assets
43151000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1258000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
934000
CY2019Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
992000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
943000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2250000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1877000
CY2019Q1 slno Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
5855000
CY2018Q4 slno Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
5649000
CY2019Q1 us-gaap Liabilities
Liabilities
15236000
CY2018Q4 us-gaap Liabilities
Liabilities
12738000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
32000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
157661000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
157413000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31776584
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19402000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23099000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
603000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
529000
CY2019Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
72000
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
64000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134062000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127032000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
23631000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
30413000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38867000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43151000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
200000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23099000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17135000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19402000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3687000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2520000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14901000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
185000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2232000
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202000
CY2018Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
-0.02
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31756120
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19530311
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
26817000
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
159000
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
82000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
23252000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31776584
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31755169
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31776584
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31755169
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2760000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1180000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2012000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1867000
CY2019Q1 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
206000
CY2018Q1 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
428000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4978000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
3475000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4978000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3475000
CY2018Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
3000
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1919000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-163000
CY2019Q1 slno Income Loss From Minority Interest Investments
IncomeLossFromMinorityInterestInvestments
-190000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
57000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2052000
CY2019Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-7030000
CY2018Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3290000
CY2018Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-514000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7030000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3804000
CY2019Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.22
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.17
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
46000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-7030000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-3804000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
489000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
492000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
202000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
341000
CY2019Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
46000
CY2018Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
82000
CY2019Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-190000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
74000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80000
CY2019Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
8000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
324000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
409000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
49000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-252000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3687000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2033000
CY2018Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-487000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10000
CY2018Q1 slno Cash Paid For The Issuance Of Common Stock And Common Stock Warrants
CashPaidForTheIssuanceOfCommonStockAndCommonStockWarrants
112000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-112000
CY2018Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
400000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
288000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3697000
CY2018Q1 slno Cash And Cash Equivalents Period Increase Decrease Included In Current Assets Held For Sale
CashAndCashEquivalentsPeriodIncreaseDecreaseIncludedInCurrentAssetsHeldForSale
-2000
CY2018Q1 slno Accrued Liability For Cost Of Issuing Common Stock
AccruedLiabilityForCostOfIssuingCommonStock
91000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.03
CY2019Q1 slno Working Capital
WorkingCapital
18600000
CY2015Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2015Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8171
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
23300
CY2015Q3 slno Lessee Leasing Arrangements Operating Leases Increasesto Monthly Payments Term
LesseeLeasingArrangementsOperatingLeasesIncreasestoMonthlyPaymentsTerm
P3Y
CY2016Q1 slno Additional Operating Lease Office Space
AdditionalOperatingLeaseOfficeSpace
5265
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
54000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
85000
CY2019Q1 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
65000
CY2018Q1 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
98000
CY2018Q4 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
2000000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
202000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
359000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.026
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.08
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1500000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
476000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9962085
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9599742
CY2017Q1 slno Asset Acquisition Fair Value Of Stock Consideration
AssetAcquisitionFairValueOfStockConsideration
4200000
CY2017Q1 slno Asset Acquisition Fair Value Of Cash Consideration
AssetAcquisitionFairValueOfCashConsideration
1100000
CY2017Q1 slno Asset Acquisition Consideration Transferred1
AssetAcquisitionConsiderationTransferred1
5300000
CY2019Q1 slno First Commercial Sales Milestone
FirstCommercialSalesMilestone
100000000
CY2019Q1 slno Second Commercial Sales Milestone
SecondCommercialSalesMilestone
200000000
CY2019Q1 slno Contingent Liability Payment On Achievement Of Sales Milestone
ContingentLiabilityPaymentOnAchievementOfSalesMilestone
5900000
CY2017Q1 slno Contingent Liability Payment On Achievement Of Sales Milestone
ContingentLiabilityPaymentOnAchievementOfSalesMilestone
2600000

Files In Submission

Name View Source Status
0001564590-19-018686-index-headers.html Edgar Link pending
0001564590-19-018686-index.html Edgar Link pending
0001564590-19-018686.txt Edgar Link pending
0001564590-19-018686-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-10q_20190331.htm Edgar Link pending
slno-20190331.xml Edgar Link completed
slno-20190331.xsd Edgar Link pending
slno-20190331_cal.xml Edgar Link unprocessable
slno-20190331_def.xml Edgar Link unprocessable
slno-20190331_lab.xml Edgar Link unprocessable
slno-20190331_pre.xml Edgar Link unprocessable
slno-ex311_9.htm Edgar Link pending
slno-ex312_8.htm Edgar Link pending
slno-ex321_6.htm Edgar Link pending
slno-ex322_7.htm Edgar Link pending